Enabling success in lead identification
A crucial part of identifying novel leads is the diversity and suitability of the molecules to be screened which in turn will determine the likelihood of obtaining viable chemical starting points for new projects. How do you strike the balance between compound diversity and the ability to rapidly validate and select the most promising hits for follow up?
In this talk we will share our view of the best strategies for building libraries to maximise the probability of identifying tractable hit series for a range of target classes. Having created multiple compound libraries which have been selected and filtered computationally but also assessed individually by experienced medicinal chemists we present our experience on how best to optimize this process to provide highly relevant lead-like starting points for client projects.